Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Epione 369 is a nutraceutical dietary supplement developed by Epione Pharmaceuticals, formulated as a balanced blend of Omega-3, Omega-6, and Omega-9 fatty acids. Typically derived from botanical sources such as flaxseed oil, these fatty acids serve as essential structural components of cellular membranes and act as precursors to bioactive lipid mediators like eicosanoids. Omega-3 and Omega-6 are essential fatty acids that must be obtained through diet, while Omega-9 is a non-essential fatty acid that supports metabolic health. The supplement is intended to promote general wellness, specifically targeting cardiovascular health, cognitive function, and the maintenance of healthy skin and joints by modulating inflammatory pathways and supporting lipid metabolism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Epione 369.